Creative Biolabs is a global leading company which focuses on antibody development. With our extensive experience and advanced platform, we have won a good reputation among our worldwide customers for successfully accomplishing a wide variety of antibody services. Based on years of effort and senior scientists, we are now providing therapeutic IgE antibody discovery and related development services to universal customers.
Introduction to IgE Antibodies
IgE, also known as immunoglobulin E, is a member of the immunoglobulin family and usually is produced by mature B cells in mammals. In general, IgE monomer is comprised of two heavy chains (ε type) and two light chains (κ or λ type), each chain has a variable region, and each heavy chain has four constant regions. The variable region is responsible for binding to specific antigens and the constant region is the key to activate effector functions against infection. Functionally, IgE plays an important role in triggering an immune response against a wide variety of parasites, such as Schistosoma mansoni, Plasmodium falciparum, as well as Fasciola hepatica. Furthermore, various studies have revealed that IgE can actively bind to two receptors, high-affinity receptor FcεRI (Fc epsilon receptor I) and low-affinity receptor FcεRII (CD23). FcεRI is mostly expressed in a number of human cells, including basophils, mast cells (MC), dendritic cells (DC), macrophages, as well as platelets, while FcεRII is mainly found on mature B cells. In addition, IgE antibodies can also be produced by activating an immune response against allergens, and each type of IgE can defense a specific allergen by type I hypersensitivity, which suggests the diversity of IgE antibodies in mammals as well as the fundamental role of IgE in allergy.
Fig. 1 Structure of IgE. (Novosad, 2020)
Therapeutic Effect of IgE Antibodies
Despite being the least abundant isotype in serum, the IgE antibody has been suggested to play an essential role in mediating a series of immune responses in parasitic infection and triggering powerful inflammatory reactions. More importantly, current studies have highlighted that IgE antibody should be a perfect potential therapeutic candidate for the different types of tumors, such as leukemia, breast carcinoma, pancreatic cancer, etc. Tumor-specific serum IgE is significantly increased in cancer patients and immunohistochemistry results indicate IgE antibody is the most abundant class in the tumor tissues. It is concluded that IgE antibody may present stronger immune surveillance and superior anti-tumor effects over IgG monoclonal antibody since that (i) IgE binds to FcεRs with high affinity; (ii) IgE can regulate specific effector cells, such as MC, basophils, to better recognize tumor antigens, and thereby enhance local tumor cell killing meanwhile inducing a secondary anti-tumor response.
Therefore, considering the excellent anti-tumor effects of IgE antibody, Creative Biolabs has established a special team for non-IgG antibodies development in order to provide a diversity of IgE therapeutic antibody products and comprehensive services for our global clients.
Fig.2 Scheme of possible IgE-mediated interactions between effector cells and targeted tumor cells. (Leoh, 2015)
Creative Biolabs is recognized as the world leader for providing the most diverse portfolio of the non-lgG therapeutic antibodies products and solutions for worldwide customers. We have accumulated extensive experience from the accomplishment projects and are confident in providing high-quality and omnidirectional non-IgG antibody services to meet any special needs of your research.
For more detailed information, please feel free to contact us or directly sent us an inquiry.
- Novosad, J., and Krčmová, I. Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today? International Journal of Immunopathology and Pharmacology. 2020, 34.
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.